US2021008042A1PendingUtilityA1

Treatment methods utilizing stem cell mobilizers and immunosuppressive agents

70
Assignee: MEDREGEN LLCPriority: Dec 11, 2009Filed: Sep 22, 2020Published: Jan 14, 2021
Est. expiryDec 11, 2029(~3.4 yrs left)· nominal 20-yr term from priority
Inventors:Zhaoli SunGeorge Williams
A61K 31/395A61K 9/0095A61K 9/10A61K 9/0019A61K 9/08A61K 9/4841A61K 9/2004A61K 9/107A61K 38/19A61K 38/18A61K 31/506A61K 31/4427A61K 31/365A61P 37/06A61P 9/10A61P 17/00A61P 13/12A61P 1/16A61K 31/00A61K 31/436A61K 38/13A61K 38/193A61K 45/06
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention related to the field of organ transplantation. In one aspect, the present invention provides methods of treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method of treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of immunosuppressive agent.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . A method of treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. 
     
     
         2 . The method of  claim 1 , wherein the organ is selected from the group consisting of liver, kidney, skin, heart, lung, intestine, and pancreas. 
     
     
         3 . The method of  claim 1 , wherein the organ is liver, kidney and/or skin. 
     
     
         4 . The method of  claim 1 , wherein the stem cell mobilizer is selected from the group consisting of AMD3100, AMD3465, TG-0054, G-CSF, GM-CSF, SDF-1, and SCF. 
     
     
         5 . The method of  claim 1 , wherein the stem cell mobilizer is a CXCR4 antagonist. 
     
     
         6 . The method of  claim 5 , wherein the stem cell mobilizer is AMD3100. 
     
     
         7 . The method of  claim 1 , wherein the immunosuppressive agent is selected from the group consisting of Tacrolimus, cyclosporine, Orthoclone OKT3, mycophenolate, and sirolimus. 
     
     
         8 . The method of  claim 7 , wherein the immunosuppressive agent is Tacrolimus. 
     
     
         9 . The method of  claim 1 , wherein the immunosuppressive agent is administered in a low dose amount. 
     
     
         10 . A method of treating a patient diagnosed with ischemic injury or a tissue or organ transplant recipient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. 
     
     
         11 . The method of  claim 10 , wherein the stem cell mobilizer is ANID3100. 
     
     
         12 . The method of  claim 10 , wherein the immunosuppressive agent is Tacrolimus. 
     
     
         13 . The method of  claim 10 , wherein the stem cell mobilizer is ANID3100 and the immunosuppressive agent is Tacrolimus.

Join the waitlist — get patent alerts

Track US2021008042A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.